InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Scopa James Paul, Director. Officer active across 4 companies, notably DICE Therapeutics, Inc.. Cumulatively, 13 disclosures have been published. Breakdown: 3 buys · 2 sells. Total volume traded: €489k. History available since 15 September 2021. The latest transaction was filed on 7 February 2024 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations13 total
100,000 shares@ US$1.3539.7% of flowCommon StockSEC:0001415889-24-003209:0
Ideal exit: 3 Nov 2024 (T+270)
183,083 shares@ US$0.7568100.0% of flowCommon StockSEC:0001610717-23-000318:0
15,199 sharesCommon StockSEC:0001209191-23-045182:0
220 shares0Common StockSEC:0001209191-23-044546:0
2,200 shares0Common StockSEC:0001209191-23-042750:0
300 shares0Common StockSEC:0001209191-23-042235:0
6,923 shares0Common StockSEC:0001209191-23-026618:0
30,719 shares0Common StockSEC:0001209191-23-020299:0
50,000 shares@ US$2.1830.1% of flowCommon StockSEC:0001209191-21-065115
50,000 shares@ US$2.1850.0% of flowCommon StockSEC:0001209191-21-065115:0
6,000 shares@ US$17.0050.0% of flowCommon StockSEC:0001209191-21-056526:0
Ideal exit: 12 Jun 2022 (T+270)
6,000 shares@ US$17.0050.0% of flowCommon StockSEC:0001209191-21-056526
Ideal exit: 12 Jun 2022 (T+270)
1,776,692 sharesCommon StockSEC:0001209191-16-095658:0
13 of 13 declarations
About Scopa James Paul
James Paul Scopa is a Board Member at DICE Therapeutics, Inc. and Adverum Biotechnologies, Inc. He participates in overseeing operations and strategic decision-making for both companies. James brings expertise in biotechnology, contributing to the innovation and growth of these firms.
